ARS Investment Partners LLC Purchases 15,000 Shares of Humacyte, Inc. (NASDAQ:HUMA)

ARS Investment Partners LLC increased its position in Humacyte, Inc. (NASDAQ:HUMA) by 17.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 99,419 shares of the company’s stock after buying an additional 15,000 shares during the quarter. ARS Investment Partners LLC owned 0.08% of Humacyte worth $502,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Renaissance Technologies LLC increased its stake in shares of Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares during the period. State Street Corp increased its position in Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after purchasing an additional 1,895,529 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Humacyte during the 3rd quarter valued at approximately $596,000. Thrivent Financial for Lutherans acquired a new stake in Humacyte during the 3rd quarter valued at approximately $712,000. Finally, Barclays PLC boosted its holdings in shares of Humacyte by 177.6% during the 3rd quarter. Barclays PLC now owns 236,742 shares of the company’s stock worth $1,288,000 after buying an additional 151,458 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on HUMA. Piper Sandler set a $6.00 price target on Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. TD Cowen restated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Monday, January 13th. Finally, Benchmark upped their price objective on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Humacyte currently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Down 1.6 %

HUMA stock opened at $4.41 on Tuesday. Humacyte, Inc. has a twelve month low of $2.53 and a twelve month high of $9.97. The stock has a market cap of $555.04 million, a P/E ratio of -3.29 and a beta of 1.32. The business’s 50-day moving average price is $4.55 and its 200-day moving average price is $5.65.

Insiders Place Their Bets

In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the sale, the chief executive officer now directly owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last quarter. 11.20% of the stock is currently owned by insiders.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.